Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States

[1]  S. Neggers,et al.  Use of Oral Concomitant Medications in Patients With Acromegaly , 2021, Journal of the Endocrine Society.

[2]  S. Melmed,et al.  The Pharmacological Burden of Comorbidities in Acromegaly , 2021, Journal of the Endocrine Society.

[3]  Jonathan D. Campbell,et al.  Economic and clinical burden of comorbidities among patients with acromegaly. , 2021, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[4]  P. Paśko,et al.  Optimal Dosing Regimen of Osteoporosis Drugs in Relation to Food Intake as the Key for the Enhancement of the Treatment Effectiveness—A Concise Literature Review , 2021, Foods.

[5]  A. Luger,et al.  Hypertension in Acromegaly in Relationship to Biochemical Control and Mortality: Global ACROSTUDY Outcomes , 2020, Frontiers in Endocrinology.

[6]  Deepak L. Bhatt,et al.  2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution S , 2020, Journal of the American College of Cardiology.

[7]  S. Samson,et al.  A Pituitary Society update to acromegaly management guidelines , 2020, Pituitary.

[8]  L. Kasuki,et al.  Novel therapies for acromegaly , 2020, Endocrine connections.

[9]  Lizheng Shi,et al.  Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice , 2020, BMC Endocrine Disorders.

[10]  M. Kamusheva,et al.  New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria , 2020, Frontiers in Public Health.

[11]  M. Fleseriu,et al.  An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies , 2020, Pituitary.

[12]  S. Melmed.  Pituitary-Tumor Endocrinopathies. , 2020, The New England journal of medicine.

[13]  F. Casanueva,et al.  A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. , 2020, The Journal of clinical endocrinology and metabolism.

[14]  J. Alpert.  Take-Home Messages From the Recently Updated AHA/ACC Guidelines for Atrial Fibrillation , 2019 .

[15]  Hyo-Jick Choi,et al.  Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals , 2019, Pharmaceutics.

[16]  M. Fleseriu,et al.  Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update. , 2018, Endocrine reviews.

[17]  M. Kołtowska-Häggström,et al.  Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy , 2018, Endocrine.

[18]  Salma M. AlDallal.  Acromegaly: a challenging condition to diagnose , 2018, International journal of general medicine.

[19]  P. Chanson,et al.  A Consensus Statement on acromegaly therapeutic outcomes , 2018, Nature Reviews Endocrinology.

[20]  M. Akker,et al.  Patients with multimorbidity and their treatment burden in different daily life domains: a qualitative study in primary care in the Netherlands and Belgium. , 2018 .

[21]  P. Rataboli,et al.  A study of harmful drug–drug interactions due to polypharmacy in hospitalized patients in Goa Medical College , 2017, Perspectives in clinical research.

[22]  Hyejeong Kim,et al.  Effective method for drug injection into subcutaneous tissue , 2017, Scientific Reports.

[23]  P. Chanson,et al.  Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database , 2017, Endocrine-related cancer.

[24]  Clara P. Savage,et al.  Subcutaneous Injection of Testosterone Is an Effective and Preferred Alternative to Intramuscular Injection: Demonstration in Female-to-Male Transgender Patients , 2017, The Journal of clinical endocrinology and metabolism.

[25]  N. Karavitaki,et al.  Epidemiology of acromegaly: review of population studies , 2016, Pituitary.

[26]  T. Brue,et al.  The risks of overlooking the diagnosis of secreting pituitary adenomas , 2016, Orphanet Journal of Rare Diseases.

[27]  T. Chen,et al.  Medication-related burden and patients’ lived experience with medicine: a systematic review and metasynthesis of qualitative studies , 2016, BMJ Open.

[28]  Andrew T Chan,et al.  Trends in Prescription Drug Use Among Adults in the United States From 1999-2012. , 2015, JAMA.

[29]  M. Blüher,et al.  Pill Burden in Patients With Type 2 Diabetes in Germany: Subanalysis From the Prospective, Noninterventional PROVIL Study , 2015, Clinical Diabetes.

[30]  J. Ayuk,et al.  Treatment Factors That Influence Mortality in Acromegaly , 2015, Neuroendocrinology.

[31]  E. Laws,et al.  Acromegaly: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[32]  H. Blume,et al.  Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update , 2014, Drug Safety.

[33]  M. Sabbatini,et al.  Efficacy of a reduced pill burden on therapeutic adherence to calcineurin inhibitors in renal transplant recipients: an observational study , 2014, Patient preference and adherence.

[34]  B. Farrell,et al.  Reducing pill burden and helping with medication awareness to improve adherence , 2013, Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC.

[35]  A. Soto-Moreno,et al.  Neurocognitive Function in Acromegaly after Surgical Resection of GH-Secreting Adenoma versus Naïve Acromegaly , 2013, PloS one.

[36]  S. Benvenga,et al.  A Review of the Pharmacokinetics of Levothyroxine for the Treatment of Hypothyroidism. , 2013, European endocrinology.

[37]  M. Neary,et al.  Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases , 2012, Pituitary.

[38]  Bing Li,et al.  Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. , 2011, American journal of epidemiology.

[39]  R. Bushra,et al.  Food-drug interactions. , 2011, Oman medical journal.

[40]  R. Weber,et al.  Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study , 2010, Antiviral therapy.

[41]  S. Melmed.  Acromegaly pathogenesis and treatment. , 2009, The Journal of clinical investigation.

[42]  P. Caron,et al.  Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. , 2008, European journal of endocrinology.

[43]  J. Vandenbroucke,et al.  Mortality in acromegaly: a metaanalysis. , 2008, The Journal of clinical endocrinology and metabolism.

[44]  P. Caron,et al.  Effectiveness and tolerability of 3‐year lanreotide Autogel® treatment in patients with acromegaly , 2006, Clinical endocrinology.

[45]  D. Bonaduce,et al.  High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. , 2003, The Journal of clinical endocrinology and metabolism.

[46]  Valentin Fuster,et al.  American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. , 2003, Circulation.